Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance
PLOS Neglected Tropical Diseases · 18.11.2026 · 20 (11) · e0014883
DOI: 10.1371/journal.pntd.0014883 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 18.11.2026. Verfasst von Janine Wenker und 12 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency (Agence Nationale de la Recherche, ANR) – ApiNewDrug Project, French National Research Agency (ANR) – Laboratoire d'Excellence (LabEx) ParaFrap, LabEx ParaFrap.
Abstract (Originalsprache)
Background Cryptosporidiosis is a major enteric disease affecting humans and animals worldwide, with severe consequences in young children and neonatal livestock, yet treatment options remain extremely limited. Benzoxaboroles have emerged as promising broad-spectrum antiparasitic compounds, but their mechanisms of action, molecular targets, and resistance pathways in Cryptosporidium spp. remain incompletely understood, limiting their optimal therapeutic deployment. We previously showed that the benzoxaborole AN3661 inhibits the endonuclease Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) in Cryptosporidium hominis , likely by disrupting pre-mRNA processing and restricting parasite growth. Here, we further investigated the mode of action of AN3661 and compared it with two additional benzoxaboroles, AN13762 and AN7973. Methodology Cell culture assays combined with imaging-based quantification were used to assess drug activity and determine the impact of treatment on parasite growth and development. CRISPR-Cas9 genome editing was used to introduce a point mutation into Cryptosporidium parvum CPSF3 and evaluate resistance to benzoxaboroles in vitro and in vivo . Nanopore sequencing was performed to examine the effects of drug exposure on parasite mRNA processing. Principal Findings We identified a single mutation in C. parvum CPSF3 (Y385N) that conferred strong resistance to AN3661. In contrast, this mutation did not reduce sensitivity to AN13762 or AN7973, which are also suspected to target CPSF3. All three benzoxaboroles impaired mRNA processing, a process mediated by the CPSF machinery, and exhibited parasiticidal activity, with pronounced effects during late-stage maturation of first-generation meronts, including inhibition of parasite egress; two compounds also affected gametogenesis. Notably, AN7973 controlled severe infection in susceptible mice challenged with the AN3661-resistant C. parvum CPSF3 Y385N mutant. In Toxoplasma gondii , AN7973 remained active against strains resistant to AN3661 and AN13762, supporting a distinct mechanism of action. Finally, AN3661 and AN7973 were active against Eimeria tenella, and AN3661 against Giardia duodenalis . Conclusions/Significance Together, these results identify a resistance mechanism affecting AN3661 in Cryptosporidium , and highlight AN7973 as a promising alternative compound with broad antiparasitic activity and efficacy against AN3661-resistant parasites.
Förderung
- French National Research Agency (Agence Nationale de la Recherche, ANR) – ApiNewDrug Project
- French National Research Agency (ANR) – Laboratoire d'Excellence (LabEx) ParaFrap
- LabEx ParaFrap
- European Partnership on Animal Health and Welfare (EUPAHW), co-funded by the European Union under Horizon Europe
Zitieren
APA
Wenker, J., Braun, L., Swale, C., Gouin, A., Pichon, J., Mariot, J., Lombard, L., Baty, T., Dobrescu, I., Lalle, M., Hakimi, M., Bougdour, A., & Laurent, F. (2026). Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance. PLOS Neglected Tropical Diseases, 20(11), e0014883. https://doi.org/10.1371/journal.pntd.0014883
Vancouver
Wenker J, Braun L, Swale C, Gouin A, Pichon J, Mariot J, et al. Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance. PLOS Neglected Tropical Diseases. 2026;20(11):e0014883. doi:10.1371/journal.pntd.0014883
BibTeX
@article{Wenker2026,
author = {Wenker, Janine and Braun, Laurence and Swale, Christopher and Gouin, Axel and Pichon, Julien and Mariot, Julie and Lombard, Laura and Baty, Thomas and Dobrescu, Irina and Lalle, Marco and Hakimi, Mohamed-Ali and Bougdour, Alexandre and Laurent, Fabrice},
title = {Mechanistic insights into benzoxaborole activity against Cryptosporidium parvum: CPSF3 targeting genetically validated for AN3661, with implications for resistance},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
volume = {20},
number = {11},
pages = {e0014883},
doi = {10.1371/journal.pntd.0014883}
}
EUVIMED